New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 1, 2014
07:31 EDTARWRArrowhead completes enrollment of first cohort in phase 2a trial of ARC-520
Arrowhead Research Corporation announced that the first cohort of 8 patients has been fully enrolled and dosed in a Phase 2a clinical trial of ARC-520, its RNAi therapeutic for the treatment of chronic hepatitis B virus infection. The trial remains on schedule to meet the previously stated goal of completing dosing in the second quarter and releasing top line results in the third quarter. The Phase 2a study is planned to enroll up to 16 chronic HBV patients in two dose cohorts with patients receiving either ARC-520 or placebo in combination with entecavir. The study is designed to evaluate the depth and duration of hepatitis B surface antigen decline, among other measures, in response to a single dose of ARC-520.
News For ARWR From The Last 14 Days
Check below for free stories on ARWR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
14:54 EDTARWRArrowhead Research November volatility elevated into Phase IIb trial data
Subscribe for More Information
07:36 EDTARWRArrowhead outlook positive, says RBC Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use